Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12644734 | 0.86 | MAPT (0.52) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL16375430 | 0.86 | KMT2A (0.77) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL3145157 | 0.86 | KMT2A (0.77) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL13552104 | 0.85 | HGFAC (0.60) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL12644210 | 0.84 | KMT2A (0.55) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL12644214 | 0.84 | KMT2A (0.55) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL9807385 | 0.83 | ALDH1A1 (0.53) | KMT2AMAPTALDH1A1MAPK1MEN1 | |
| SCHEMBL13551974 | 0.82 | ALDH1A1 (0.47) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL10636579 | 0.82 | KMT2A (0.84) | KMT2APKMHGFACNR1H4MAPT | |
| SCHEMBL4951809 | 0.82 | KMT2A (0.84) | KMT2APKMHGFACNR1H4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771321-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2017-07-06 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | KELLY JEFFERY W (US) | 2014-11-13 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703815-B2 | Small molecules that covalently modify transthyretin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336254-A1 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | KMT2A 3072/4885PKM 2741/4885HGFAC 528/4885 |
| US-20170190660-A9 | Small Molecules That Covalently Modify Transthyretin | TTR, TTPA, APOB | KMT2A 3072/4885PKM 2741/4885HGFAC 528/4885 |
| US-20120270938-A1 | SMALL MOLECULES THAT COVALENTLY MODIFY TRANSTHYRETIN | TTR, TTPA, APOB | KMT2A 3072/4885PKM 2741/4885HGFAC 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.